ACR has it's own IP(Intellectual Property) internal code ACR065...

ACR has it's own IP(Intellectual Property) internal code ACR065 which is for toes nails as well. At the time it was announced they said it has the potential to be bigger that Axrion. But with the Axrion troubles it hasn't been mentioned again. So how many other products do they have on the books that are not part of the generic pipeline, waiting for the cash to develop, as it's been mentioned that they have spent $70 plus million on R&D since 2005? I would think that if ACR can capture 3-4% of the market with the Generic Pipeline that would be a good outcome. ACR's hands are tied by the courts re Jublia and cant say anything. Jublia currently has sales of US$280 million a year. Some US$1500 per month to fill a scrip.